Skip to main content

Table 3 Diagnostic performance of five non-invasive tests for determining significant fibrosis (METAVIR F ≥ 2)

From: Novel serum biomarkers modified by the body mass index z-score for the detection of liver fibrosis and steatosis in children with chronic hepatitis C

Significant fibrosis (METAVIR F ≥ 2)

Test

APRI

M-APRI

FIB-4

M-FIB-4

B-AST

AUROC (95% CI)

0.752 (0.561–0.890)

0.842 (0.663–0.948)

0.708 (0.514–0.859)

0.823 (0.641–0.937)

0.848 (0.670–0.952)

Cut-off

0.656

0.577

0.180

0.179

92.82

Sensitivity (95% CI)

57.1 (18.4–90.1)

71.4 (29.0–96.3)

85.7 (42.1–99.6)

71.4 (0.29–96.3)

71.4 (0.29–96.3)

Specificity (95% CI)

91.3 (72.0–98.9)

95.6 (78.1–99.9)

65.2 (42.7–83.6)

91.30 (72.0–98.9)

95.7 (78.1–99.0)

+ PV

66.7 (31.5–89.7)

83.3 (41.0–97.3)

42.9 (28.4–58.6)

71.4 (38.0–91.1)

83.3 (41.0–97.3)

- PV

87.5 (74.7–94.3)

91.7 (77.3–97.3)

93.7 (70.5–99.0)

91.3 (76.4–97.2)

91.7 (77.3–97.3)

  1. APRI aspartate-to-platelet ratio index, FIB-4 Fibrosis-4 index, M-APRI modified aspartate-to-platelet ratio index (BMI z-score x APRI), M-FIB-4 modified Fibrosis-4 index (BMI z-score x FIB-4), B-AST BMI z-score x AST, AUROC area under the receiver operating characteristic, 95% CI 95% confidence interval, + PV positive predictive value, − PV negative predictive value